## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.0% below STRENGTH zone (4.0-10.0%); PEG 1.56 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (55% of avg), momentum weakening (-6.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($35.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Centene Corp. stock underperforms Monday when compared to competitors**
- Source: MSN | 20251202T150817 | Neutral | Relevance: 99%
- Centene Corp. stock experienced an underperformance on Monday compared to its competitors. The stock closed down while its rivals saw gains, reflecting a mixed day in the market for healthcare companies. This suggests potential volatility or specific company-related factors influencing Centene's performance relative to the broader sector.

**2. Meridian Health Plan of Illinois Commits $1.15 Million to Expand St. Louis Area Foodbank Mobile Pantry Program**
- Source: ADVFN | 20251202T173900 | Somewhat-Bullish | Relevance: 98%
- Meridian Health Plan of Illinois is providing a $1.15 million grant over three years to the St. Louis Area Foodbank's "Food On The Move" mobile pantry program. This initiative, aligned with Meridian's "Eat Well, Be Well" program, aims to combat food insecurity and provide healthy food and nutrition education to underserved populations, food deserts, and rural areas across Illinois. The grant will support over 300 mobile market distributions, anticipating serving 60,000 community members through 2028, and will integrate health screenings and vaccinations starting in 2026.

**3. Why Myriad Genetics (MYGN) Stock Is Trading Lower Today**
- Source: Finviz | 20251201T123600 | Somewhat-Bullish | Relevance: 69%
-  Shares of Myriad Genetics (NASDAQ:MYGN) fell 6% after the FDA approved a competing blood-based prostate cancer test from Cleveland Diagnostics, IsoPSA. This new diagnostic kit increases competition in the prostate cancer market, raising investor concerns about Myriad's market share. Investors reacted negatively to the news, signaling increased competition in cancer diagnostics.

**4. Brown & Brown Employer Health and Benefits Strategy Survey | 2026 Edition**
- Source: Brown & Brown | 20251201T190628 | Neutral | Relevance: 63%
- Brown & Brown's second annual Employer Health and Benefits Strategy Survey for 2026 highlights rising costs, evolving workforce needs, and a focus on innovation and sustainability as key shapers of the benefits landscape. The survey, which included 1,241 employers, found a shift in strategic priorities, with cost control now topping the list for both employees and employers. Attracting and retaining a healthy and engaged workforce, previously the top priority, moved to third place.

**5. Quadrant Capital Group LLC Cuts Stock Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251202T020915 | Neutral | Relevance: 63%
-  Quadrant Capital Group LLC reduced its stake in Elevance Health, Inc. by 25.5% in the second quarter, selling 948 shares to hold 2,769 shares valued at $1.08 million. Despite this reduction by one firm, other large institutional investors like Vanguard, Sanders Capital, Nuveen, Orbis Allan Gray, and Boston Partners increased their positions in the company, with institutional ownership reaching 89.24%. Elevance Health also reported strong Q3 earnings, beating analyst expectations for both EPS and revenue, and declared a quarterly dividend of $1.71.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |
| 2025-11-12 | Wells Fargo | $35 | $41 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |
| 2025-11-12 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Long-term trend broken: trading 13.2% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.56 elevated, pricing in significant growth expectations. Forward P/E 13.3x attractive for 46% earnings growth. Balance sheet: $1.1B free cash flow. Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.0B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.56 |
| Forward P/E | 13.3 |
| Current P/E | 19.4 |
| YoY Growth | 46.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 9.4% to 3.0% (-6.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.0pp (needs >4.0% for momentum thesis). MRS_5 (-1.2%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.8% shows strong absolute momentum above own 20MA. Outperforming sector by 3.2pp, stock-specific strength. Below SMA200 (0.87x), long-term trend not supportive. RSI neutral at 58. Volume at 55% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.02% (CS: 84) | Neutral |
| RSI_14 | 57.9 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 1.048x | Above |
| vs SMA50 | 1.071x | Above |
| vs SMA200 | 0.868x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $38.81
- **Stop Loss:** $35.61 (8.2% risk)
- **Target:** $42.01 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 312
- **Position Value:** $12,108.72
- **Portfolio %:** 12.11%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*